Effects of rhBMP-2 and osteopromotive membranes on experimental bone grafting.
A problem with using autogeneic bone for onlay grafting is its degree of incorporation and volumetric persistence. This study explored whether improved graft volumetric maintenance can be achieved by recombinant human bone morphogenetic protein-2 (rhBMP-2) and whether a combination of rhBMP-2 and osteopromotive membranes is advantageous in this respect. Unicortico-cancellous bone grafts were positioned below the temporal muscle bilaterally in 48 adult Lewis rats. The recipient bone was ground, and the grafted area was randomly treated according to one of eight different alternatives. Two doses of rhBMP-2 (4 microg/80 microl or 32 microg/80 microl buffer) in a collagenous carrier were tested, with or without coverage with expanded polytetrafluoroethylene membranes. As controls, membrane and carrier, alone or in combination, and onlay grafts only were used. The results were evaluated after 4 and 20 weeks by routine histologic examination and immunohistochemical labeling for various bone and cartilage matrix proteins. After 4 weeks, rhBMP-2-treated grafts showed complete integration, whereas for controls, only the membrane-alone group attained incorporation after 20 weeks. The combined treatment with high-dose rhBMP-2 and membrane demonstrated, as compared with the remaining rhBMP-2 groups, pronounced bone formation and less graft resorption, resulting in maintained or increased graft size. This was observed after 4 weeks, and the result remained at 20 weeks. Treatment with high-dose rhBMP-2 without membrane placement, in contrast, resulted in extensive resorption and graft size reduction at 20 weeks. Control groups showed less success in graft size persistence. It was concluded that a combination of high-dose rhBMP-2 and osteopromotive membranes had a synergistic effect, leading to rapid, complete graft integration and size maintenance. In the absence of a membrane, the protein seemed to accelerate the remodeling of the graft.
Gordh
M
M
Department of Oral Surgery, Centre for Oral Health Sciences, Lund University, Malmö, Sweden. Monica.Gordh@skane.se
Alberius
P
P
Johnell
O
O
Lindberg
L
L
Linde
A
A
D000818:Animals; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001862:Bone Resorption; D016025:Bone Transplantation; D001842:Bone and Bones / Q000737:chemistry; D002352:Carrier Proteins / Q000032:analysis; D064236:Cartilage Oligomeric Matrix Protein; D016326:Extracellular Matrix Proteins / Q000032:analysis; D000071235:Fibromodulin; D006023:Glycoproteins / Q000032:analysis; D007150:Immunohistochemistry; D007797:Laminin / Q000032:analysis; D008297:Male; D064235:Matrilin Proteins; D008567:Membranes, Artificial; D010012:Osteogenesis; D011138:Polytetrafluoroethylene; D011509:Proteoglycans / Q000032:analysis; D051381:Rats; D011917:Rats, Inbred Lew; D011994:Recombinant Proteins / Q000494:pharmacology; D016212:Transforming Growth Factor beta
C525718:BMP2 protein, human; D001672:Biocompatible Materials; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D064236:Cartilage Oligomeric Matrix Protein; D016326:Extracellular Matrix Proteins; C000604330:FMOD protein, human; C000604334:Fmod protein, rat; D006023:Glycoproteins; D007797:Laminin; D064235:Matrilin Proteins; D008567:Membranes, Artificial; D011509:Proteoglycans; D011994:Recombinant Proteins; C577553:TSP5 protein, human; D016212:Transforming Growth Factor beta; D000071235:Fibromodulin; D011138:Polytetrafluoroethylene